Purchased pre-funded warrants in the January 2024 private placement
| Officer | Age | In this role | Joined | 2025 pay | Source |
|---|---|---|---|---|---|
|
Vincent J. Angotti
Also a director
Director, Chief Executive Officer
|
58 | Not stated | Not stated | $1,117,277 | |
|
Raffi Asadorian
Chief Financial Officer
|
56 |
Since 2017
9 years
|
Not stated | $727,309 | |
|
Shakil Aslam
Chief Medical Officer
|
61 |
Since 2024
2 years
|
2024 | $654,840 | |
|
Badri Dasu
Chief Engineering Officer
|
63 |
Since 2007
19 years
|
Not stated | Not reported |
Each officer opens the passage of the filing that names them. A title that changed since the list comes from the officer's latest Form 3, 4 or 5, and its start year is not stated there. "Not stated" means the filing does not say. Pay is the proxy's Summary Compensation Table, which reports only the named executive officers.
Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.
Purchased pre-funded warrants in the January 2024 private placement
Purchased pre-funded warrants in the January 2024 private placement
Purchased pre-funded warrants in the April 2025 private placement
Purchased common stock and pre-funded warrants in the April 2025 private placement
Purchased common stock in the April 2025 private placement
Purchased common stock and pre-funded warrants in the September 2025 private placement
Purchased common stock and pre-funded warrants in the September 2025 private placement
Board nomination right for Nantahala; Abhinav Jain appointed as Nantahala Board Representative (Class II Director)
Purchaser in the September 2025 private placement, first closing
Board nomination right for CorMedix; Joseph Todisco appointed as CorMedix Board Representative
Right of first negotiation over an acquisition of Talphera for 60 days after the public announcement of NEPHRO CRRT topline data
Loading...